KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by KALA BIO, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for KALA BIO, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Lazar David E. | Chief Executive Officer | – | Dec 22, 2025 | 2 |
| Brazzell Romulus K | SEE REMARKS | 35,952 | Oct 24, 2025 | 1 |
| Iwicki Mark T | Director | 103,540 | Oct 24, 2025 | 1 |
| Bazemore Todd | Director | 35,932 | Oct 24, 2025 | 1 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | 28,906 | Oct 24, 2025 | 1 |
| Kharabi Darius | CHIEF BUSINESS OFFICER | 41,760 | Oct 24, 2025 | 1 |
| Baker Julian | Other: Former 10% owner | 425,006Indirect | Oct 2, 2025 | 1 |
| Baker Felix | Other: Former 10% owner | 425,006Indirect | Oct 2, 2025 | 1 |
| Baker Bros. Advisors LP | Other: Former 10% owner | 425,006Indirect | Oct 2, 2025 | 1 |
| Baker Bros. Advisors (GP) LLC | Other: Former 10% owner | 425,006Indirect | Oct 2, 2025 | 1 |
| Perry Gregory D | Director | 13,344 | Jun 17, 2025 | 0 |
| Koven Andrew I | Director | 16,972 | Jun 17, 2025 | 0 |
| Rosen Howard B | Director | 16,240 | Jun 17, 2025 | 0 |
| Myers C. Daniel | Director | 10,374 | Jun 17, 2025 | 0 |
| Farid Marjan | Director | 10,242 | Jun 17, 2025 | 0 |
| Blumenkranz Mark S. | Director | 13,091 | Jun 12, 2024 | 0 |
| Trachtenberg Eric | SEE REMARKS | 68,066 | Jan 5, 2024 | 0 |
| Paull Robert Bradley | Director | – | Jun 17, 2022 | 0 |
| RA Capital Healthcare Fund LP | 10% Owner | 7,039,613Indirect | May 26, 2022 | 0 |
| Ra Capital Management, L.P. | 10% Owner | 7,039,613Indirect | May 26, 2022 | 0 |
| Kolchinsky Peter | 10% Owner | 7,039,613Indirect | May 26, 2022 | 0 |
| Shah Rajeev M. | 10% Owner | 7,039,613Indirect | May 26, 2022 | 0 |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | 204,515 | Oct 28, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 29, 2022 (view filing)8:11 PM ET | Jun 27 | 2 days | Brazzell Romulus KSEE REMARKS | SSale | −3.14K | $0.37 | −$1.16K | −1.1%285.2K after | |
| Jun 29, 2022 (view filing)8:10 PM ET | Jun 27 | 2 days | Bazemore ToddSEE REMARKS | SSale | −3.09K | $0.37 | −$1.14K | −2.6%115.5K after | |
| Jun 29, 2022 (view filing)8:09 PM ET | Jun 27 | 2 days | Iwicki Mark TCHIEF EXECUTIVE OFFICER | SSale | −7.97K | $0.37 | −$2.95K | −3.1%251.2K after | |
| May 26, 2022 (view filing)5:09 PM ET | May 26 | Same day | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −1.01M | $0.3636 | −$365.7K | −12.5%7.04M after | |
| May 25, 2022 (view filing)5:17 PM ET | May 23-25 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −2.83M | $0.5262 | −$1.49M | −26.0%8.05M after | 3 lots |
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Reumuth MaryCHIEF FINANCIAL OFFICER | SSale | −2.85K | $1.30 | −$3.71K | −2.1%133.2K after | |
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Brazzell Romulus KSEE REMARKS | SSale | −3.50K | $1.30 | −$4.56K | −1.2%288.3K after | |
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Bazemore ToddSEE REMARKS | SSale | −3.45K | $1.30 | −$4.49K | −2.8%118.6K after | |
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Iwicki Mark TCHIEF EXECUTIVE OFFICER | SSale | −9.52K | $1.30 | −$12.4K | −3.5%259.2K after | |
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Trachtenberg EricSEE REMARKS | SSale | −2.85K | $1.30 | −$3.71K | −2.4%113.8K after | |
| Oct 28, 2021 (view filing) | Oct 26-27 | 2 days | Chen HongmingCHIEF SCIENTIFIC OFFICER | SSale | −30.5K | $1.81 | −$55.3K | −13.0%204.5K after | 2 lots |
| Oct 28, 2021 (view filing) | Oct 26 | 2 days | Trachtenberg EricSEE REMARKS | SSale | −9.45K | $1.80 | −$17.0K | −7.5%116.7K after | |
| Oct 28, 2021 (view filing) | Oct 26 | 2 days | Reumuth MaryCHIEF FINANCIAL OFFICER | SSale | −9.45K | $1.80 | −$17.0K | −6.5%136.1K after | |
| Oct 28, 2021 (view filing) | Oct 26 | 2 days | Bazemore ToddCHIEF OPERATING OFFICER | SSale | −12.5K | $1.80 | −$22.6K | −9.3%122.0K after | |
| Oct 28, 2021 (view filing) | Oct 26 | 2 days | Brazzell Romulus KCHIEF MEDICAL OFFICER | SSale | −12.8K | $1.80 | −$23.0K | −4.2%291.8K after | |
| Oct 28, 2021 (view filing) | Oct 26 | 2 days | Iwicki Mark TCHIEF EXECUTIVE OFFICER | SSale | −27.6K | $1.80 | −$49.7K | −9.3%268.7K after |